Irritable Bowel Syndrome Treatment Market

Global Market Study on Irritable Bowel Syndrome Treatment: North America to Remain Leading Regional Market through 2031

Irritable Bowel Syndrome Treatment Market Segmented By Fiber Supplements, Anticholinergic and Antispasmodic, Anti-Diarrheal, Antidepressants, Antibiotics, Alosetron, Lubiprostone, Linaclotide, NHE3 Drug with Constipation, Diarrhea Indication

  • September-2021
  • PMRREP9938
  • 259 Pages
  • Healthcare
  • PPT, PDF, WORD, EXCEL

Market Snapshot

Global demand for irritable bowel syndrome treatment drugs is expected to experience significant increase at 8.7% CAGR from 2021 to 2031, from an estimated market value of around US$ 3.2 Bn as of 2021. As per Persistence Market Research’s projections, irritable bowel syndrome with constipation, by indication, held a substantial share of over 48% in 2020, thereby driving market growth considerably.

Find Out More about the Report Coverage

Companies

  • Takeda Pharmaceutical Company Limited
  • Pfizer, Inc.
  • Abbott Laboratories
  • Novartis AG
  • AstraZeneca PLC
  • Ironwood Pharmaceuticals Inc. and Allergan Plc
  • Bausch Health Companies Inc.
  • GlaxoSmithKline, Plc.
  • Lexicon Pharmaceuticals, Inc.
  • Sucampo Pharmaceuticals, Inc.

Key Insights Covered in Irritable Bowel Syndrome Treatment Industry Survey:

  • Market Estimates and Forecasts (2016-2031)
  • Key Drivers and Restraints Shaping Market Growth
  • Segment-wise, Country-wise, and Region-wise Analysis
  • Competition Mapping and Benchmarking
  • Market Share Analysis By Key Players
  • Key Product Innovations and Regulatory Climate
  • COVID-19 Impact on Demand for Irritable Bowel Syndrome Treatment and How to Navigate
  • Recommendation on Key Winning Strategies

Customize this Report

Explore Intelligence Tailored to Your Business Goals.

Sales Analysis of Irritable Bowel Syndrome Treatment Drugs from 2016 to 2020 Vs Market Outlook for 2021 to 2031

The global market for irritable bowel syndrome treatment expanded at 7.7% CAGR over the past 5 years.

Irritable bowel syndrome through the development of various symptoms associated with it, such as weight loss and stomach cramping, have impacted the health of individuals suffering from gastrointestinal disorders. Awareness is also progressively being increased by governments, leading to initiatives such as the IBS Awareness month of April. Such initiatives are helping increase the number of persons getting access to irritable bowel syndrome treatment.

Increase in the use of various irritable bowel syndrome treatment drug types such as anti-diarrheal drugs and alosetron as measures for treatment other than conventional therapeutic means has led to efficient management of irritable bowel syndrome, and has subsequently resulted in higher market growth.

The global market is expected to surge at a considerable growth rate over the next ten years at a CAGR of around 8.7%, and offer an absolute $ opportunity of US$ 4.1 Bn by 2031.

Market Research Methodology - Perfected through Years of Diligence

A key factor for our unrivaled market research accuracy is our expert- and data-driven research methodologies. We combine an eclectic mix of experience, analytics, machine learning, and data science to develop research methodologies that result in a multi-dimensional, yet realistic analysis of a market.

Get actionable insights on Ship Repair And Maintenance Services Market

What Opportunities Can Irritable Bowel Syndrome Treatment Drug Manufacturers Look Out For?

The global irritable bowel syndrome treatment market is seeing elaborative strategies by key players and manufacturers. Growing prevalence of irritable bowel syndrome alternating diarrhea and constipation as well impact of dietary factors on gut health have given rise to research & development advancements in the pharmaceutical industry.

Development of advanced mechanisms of action to improve patient experience, such as a revamped study (2020) to introduce doses of chenodeoxycholic acid (CDC) by the Brigham and Women's Hospital and the Massachusetts Institute of Technology (MIT) and its delivery in a bilayered capsule to reduce cramping and provide relief in constipation, has led to wider acceptance of newer drug designs and formulations.

Impact on the irritable bowel syndrome treatment industry is also visualized by the development of online distribution channels. Advantages of online distribution channels have led to positive influence on the sales and revenue for manufacturers. Alleviation in the prices of drugs due to online discounts offered also encourage consumers to opt for treatment with effective results.

Explore Persistence Market Research’s expertise in promulgation of the business !

What are the Factors Restraining Demand for Irritable Bowel Syndrome Treatment?

There are prevailing social as well as economic factors restraining the demand growth of irritable bowel syndrome treatment. The burden of impact of prevalence of irritable bowel syndrome in developing economies and lack of awareness with regard to the symptoms leading to irritable bowel syndrome have hurt industry expansion.

Furthermore, internalized stigma of not consulting a physician for irritable bowel syndrome due to reported embarrassment or shame has led to under-diagnosis of IBS, and thus poses a burden on patient health and wellbeing.

Several studies have reported healthcare professionals as the cause of perception of internalized stigmatization of irritable bowel syndrome treatment, implying the preference of physicians on severe conditions related to gastroenterological health and trivializing the conditions of patients with mild symptoms of irritable bowel syndrome.

Additionally, presence of a large number of potential players in the industry has led to pricing competition among manufacturers, leading to restraint in the adoption of irritable bowel syndrome treatment.

irritable-bowel-syndrome-treatment-market

Country-wise Insights

What Makes the U.S. the Largest Market for Irritable Bowel Syndrome Treatment?

The U.S. dominates the North American region with a total market share of 91.4% in 2021, and is projected to continue experiencing high growth throughout the forecast period.

Growth of this market is driven by changes in lifestyle and eating habits (intake of junk and oily foods), limited physical activity, and easy availability of therapeutic drugs, resulting in high share of the country in the market for irritable bowel syndrome treatment in the region.

Why is the U.K. Considered a Lucrative Market for Irritable Bowel Syndrome Treatment in Europe?

The U.K. dominates the European with a share of 17.6% in 2021. Globally, per capita healthcare spending is on the rise. People's willingness and ability to spend on wellness has resulted in significant shift in healthcare spending.

According to the National Health Service (NHS), there is an underlying cost pressure that makes the efficient use of resources as overriding. It has been estimated that at least 12% of the population in the U.K. is affected by irritable bowel syndrome.

Will South Korea Be an Emerging Market for Irritable Bowel Syndrome Treatment?

South Korea holds 2.1% share in the East Asia market, and is projected to expand at a CAGR of 7.8%.

Investigative studies related to the relevance of Korean dietary requirements and the prevalence of irritable bowel syndrome is a key factor driving market growth.

  • For instance, a community-based survey of the general Korean population in the age group between 20 – 40 and their dietary status, by a collaborative study between Gastroenterology and Digestive Disease Research Institute, Institute of Life Science, and Natural Resources and Department of Food and Nutrition from Wonkwang University, Korea, revealed the potential cause of irritable bowel syndrome in adult Korean population, and attributed it to the presence of high fat food and high FODMAP food consumption.

What is the Outlook for China Regarding Irritable Bowel Syndrome Treatment?

In 2020, China dominated the East Asia market with 63% share, and is projected to expand at a CAGR of 7.4% from 2021 to 2031. Prevalence of irritable bowel disease in China varies between different regions and populations.

Manufacturers are focusing on expanding their global presence and specialized expertise with exclusive technological capabilities, which leads to better availability of irritable bowel syndrome treatment products in China.

  • For instance, in January 2019, AstraZeneca announced that its partner Ironwood Pharmaceuticals, Inc. has received marketing authorisation from the National Medical Products Administration (NMPA) for Linzess (linaclotide) in China for the treatment of adult patients with irritable bowel syndrome with constipation.

Category-wise Insights

Which Irritable Bowel Syndrome Treatment Drug is Driving Market Growth?

By drug type, Alosetron is set to project lucrative growth at a CAGR of 12.1% through the forecast period.

High demand for this drug type is due to the efficiency of Alosetron as an antagonist for the management of severe diarrhea predominant irritable bowel syndrome in women, which was previously not fulfilled by conventional methods.

Why is Irritable Bowel Syndrome with Alternating Constipation and Diarrhea a Concerning Factor?

Irritable bowel syndrome with alternating constipation and diarrhea holds a revenue share of 24% in 2021, but is projected to hold lesser share over the forecast period at 18.1% by 2031.

Reduced market revenue share is associated with the lack of set diagnostic measures for irritable bowel syndrome with alternating constipation and diarrhea, as well as the lack of treatment for the syndrome.

Which Distribution Channel is Most Preferred for Irritable Bowel Syndrome Treatment Drug Sales?

Based on distribution channel, retail pharmacies lead the way with more than 30% market share in 2021. Growing awareness about irritable bowel syndrome treatment and accessible measures for treatment are driving the growth of retail pharmacies in this market.

What is the Impact of COVID-19 on the Market?

The COVID-19 pandemic has projected an increase in psychological distress and rise of gastrointestinal symptoms among individuals. The resultant impact is due to high anxiety and stress leading to physiological comorbidities.

Growing adoption of online distribution channels by key manufacturers has impacted revenue generation as well as sales of products. This is facilitated by higher product reach as well as increasing awareness among the general population regarding the symptoms related to irritable bowel syndrome.

Moreover, due to impositions of lockdown in many regions, consumers opted for online measures for prescribed as well as non-prescribed drugs for the treatment of irritable bowel syndrome.

Competitive Space?

Considering consolation activities in the global market, mergers and acquisitions have emerged as one of the key growth strategies by market players. Prominent players are strengthening their product ranges through acquisitions and reaching out to key as well as emerging markets.

For instance:

  • In August 2019, GlaxoSmithKline plc completed the acquisition of the consumer healthcare business of Pfizer Inc., thus essentially accommodating a joint venture for expansion of its product portfolio, including the gastroenterology segment.

Similarly, recent developments related to companies manufacturing irritable bowel syndrome treatment products have been tracked by the team at Persistence Market Research, which are available in the full report.

Report Scope as per Irritable Bowel Syndrome Treatment Industry Analysis

Attribute

Details

Forecast Period

2021-2031

Historical Data Available for

2016-2020

Market Analysis

US$ Mn for Value

Key Regions Covered

  • North America
  • Latin America
  • Europe
  • South Asia and Pacific
  • East Asia
  • Middle East & Africa

Key Countries Covered

  • US
  • Canada
  • Brazil
  • Mexico
  • Argentina
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Benelux
  • Russia
  • China
  • Japan
  • South Korea
  • India
  • Thailand
  • Indonesia
  • Malaysia
  • Thailand
  • Indonesia
  • Australia and New Zealand
  • Turkey
  • South Africa
  • GCC Countries

Key Market Segments Covered

  • Drug Type
  • Indication
  • Distribution Channel
  • Region

Key Companies Profiled

  • Takeda Pharmaceutical Company Limited
  • Pfizer, Inc.
  • Abbott Laboratories
  • Novartis AG
  • AstraZeneca PLC
  • Ironwood Pharmaceuticals Inc. and Allergan Plc
  • Bausch Health Companies Inc.
  • GlaxoSmithKline, Plc.
  • Lexicon Pharmaceuticals, Inc.
  • Sucampo Pharmaceuticals, Inc.

Pricing

Available upon Request

Key Segments Covered in Irritable Bowel Syndrome Treatment Industry Research

By Drug Type

  • Fiber Supplements
  • Anti-Diarrheal
  • Anticholinergic and Antispasmodic
  • Antidepressants
  • Antibiotics
  • Alosetron
  • Lubiprostone
  • Linaclotide
  • NHE3

By Indication

  • Irritable Bowel Syndrome with Constipation
  • Irritable Bowel Syndrome with Diarrhea
  • Irritable Bowel Syndrome with alternating Constipation and Diarrhea

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Online Pharmacies and Stores
  • Hypermarkets and Supermarkets

Enquiry before Buying

  • Is the market research conducted by Persistence Market Research?

    Yes, the report filled with Irritable Bowel Syndrome Treatment market insights has been compiled by expert analysts of Persistence Market Research, through a combination of primary and secondary research. To know more about how the research was conducted, you can speak to a research analyst.

  • What research methodology is followed by Persistence Market Research?

    Persistence Market Research follows a methodology that encompasses the demand-side assessment and triangulates the same through a supply-side analysis. This methodology is based on the use of standard market structure, methods, and definitions.

  • Who are the respondents for primary research?

    Persistence Market Research speaks to stakeholders across the spectrum, including C-level executives, distributors, product manufacturers, and industry experts. For a full list of primary respondents, please reach out to us.

  • What are the sources of secondary research?

    Persistence Market Research conducts extensive secondary research through proprietary databases, paid databases, and information available in the public domain. We refer to industry associations, company press releases, annual reports, investor presentations, and research papers. More information about desk research is available upon request.

  • Is a sample of this report available for evaluation?

    Yes, you can request a sample, and it will be sent to you through email.

  • How can I buy this report?

    Persistence Market Research provides a secure online payment system to buy reports seamlessly. You can buy the report securely and safely.

Media Release

- FAQs -

The global irritable bowel syndrome treatment market is worth US$ 2.9 Bn at present, and is set to expand 2.2X over the next ten years.
The market is expected to reach US$ 7.3 Bn by the end of 2031, with sales revenue expected to register 8.7% CAGR.
From 2016-2020, the market expanded at the rate of 7.7%, owing to rise in gastrointestinal disorders across the globe.
Increasing awareness and government initiatives toward irritable bowel syndrome and key players acquiring other companies and brands are key trends being witnessed in this marketplace.
The U.S., China, India, U.K., and Germany are expected to drive most demand for irritable bowel syndrome treatment products.
North America is one of the key markets for irritable bowel syndrome treatment, with the U.S. expected to account over 91% of the North American market.
Demand for irritable bowel syndrome treatment in Europe is expected to register growth of 9% over the next ten years.
The U.S., China, Germany, U.K., and India are key producers of irritable bowel syndrome treatment products.
The South Korea market appears to hold the least share in East Asia, but is expected to exhibit lucrative growth at a CAGR of 7.8%. Japan holds a revenue share of 34.8% in this regional market.
The global irritable bowel syndrome treatment market is worth US$ 2.9 Bn at present, and is set to expand 2.2X over the next ten years.
The market is expected to reach US$ 7.3 Bn by the end of 2031, with sales revenue expected to register 8.7% CAGR.
From 2016-2020, the market expanded at the rate of 7.7%, owing to rise in gastrointestinal disorders across the globe.
Increasing awareness and government initiatives toward irritable bowel syndrome and key players acquiring other companies and brands are key trends being witnessed in this marketplace.
The U.S., China, India, U.K., and Germany are expected to drive most demand for irritable bowel syndrome treatment products.
North America is one of the key markets for irritable bowel syndrome treatment, with the U.S. expected to account over 91% of the North American market.
Demand for irritable bowel syndrome treatment in Europe is expected to register growth of 9% over the next ten years.
The U.S., China, Germany, U.K., and India are key producers of irritable bowel syndrome treatment products.
The South Korea market appears to hold the least share in East Asia, but is expected to exhibit lucrative growth at a CAGR of 7.8%. Japan holds a revenue share of 34.8% in this regional market.

Recommendations

Dental Implants Market

The global dental implants market is valued at nearly at US$ 4.2 Bn in 2021, and is expected to expand 2 X by 2031. The U.S. market for dental implants is valued at around US$ 850 Mn in 2021, with more 3.5 Mn implants carried out each year..

Alopecia Treatment Market

Global Market Study on Alopecia Treatment: High Demand for Effective Hair Loss Treatment. Explore it's market share, size, CAGR, revenue, trends, key players & forecast.

Compression Therapy Devices Market

Global Compression Therapy Devices Market - explore share, size, revenue, valuation, CAGR, regional outlook, key players, competitive landscape, current trends & forecast.

Next Generation Antibody Therapeutics Market

Global Next-Generation Antibody Therapeutics Market with the revenues expected to reach a value of US$ 6.76 Bn by 2022 end, up from US$ 2.25 Bn observed in 2015.

Our Clients

Our Clients